Yang Guo-Qing, Lu Ju-Ming, Liu Hong-Fang, Ma Fang-Ling, Zou Xiao-Man, Pan Chang-Yu
Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China.
Zhonghua Nei Ke Za Zhi. 2005 Jan;44(1):38-41.
To study the effect of pioglitazone on plasma homocysteine in insulin resistant rats induced by high-fat diet.
24 Wistar rats were randomized into 3 groups: a control group (n = 8) was fed with normal feeds. High-fat diet was given to a high-fat group and a pioglitazone group. Pioglitazone (10 mg/kg) was then administered by gavage daily for 11 weeks to the pioglitazone group. At week 11, glucose tolerance test was performed, and serum insulin, fasting glucose and plasma homocysteine were detected. Visceral adipose was weighted and then the ratio of visceral adipose over body weight calculated.
Fasting glucose, fasting insulin, insulin resistance index (HOMA IR), and the visceral adipose were significantly different among the 3 groups. Fasting glucose, fasting insulin, HOMA IR, and visceral adipose were all significantly lower in the pioglitazone group than those in the high fat group (P < 0.01). Plasma homocysteine decreased significantly in the pioglitazone-treated rats [(8.8 +/- 1.39) micromol/L] as compared with the other two groups [control group: (9.95 +/- 2.40) micromol/L and high fat group: (35.7 +/- 14.1) micromol/L]. Correlation analysis showed that fasting glucose, fasting insulin, HOMA IR and visceral adipose were all factors influencing the plasma homocysteine. Stepwise regression test showed only fasting glucose (r = 0.504, P = 0.031) and HOMA IR (r = 0.302, P = 0.046) independently affected the level of plasma homocysteine.
It is concluded that pioglitazone can lower plasma homocysteine in insulin resistant Wistar rats induced by high-fat diet.
研究吡格列酮对高脂饮食诱导的胰岛素抵抗大鼠血浆同型半胱氨酸的影响。
将24只Wistar大鼠随机分为3组:对照组(n = 8)给予正常饲料。高脂组和吡格列酮组给予高脂饮食。然后吡格列酮组每天经口灌胃给予吡格列酮(10 mg/kg),持续11周。在第11周时,进行葡萄糖耐量试验,并检测血清胰岛素、空腹血糖和血浆同型半胱氨酸。称量内脏脂肪,然后计算内脏脂肪与体重的比值。
3组间空腹血糖、空腹胰岛素、胰岛素抵抗指数(HOMA-IR)和内脏脂肪有显著差异。吡格列酮组的空腹血糖、空腹胰岛素、HOMA-IR和内脏脂肪均显著低于高脂组(P < 0.01)。与其他两组相比,吡格列酮治疗的大鼠血浆同型半胱氨酸显著降低[(8.8 ± 1.39)μmol/L],对照组为[(9.95 ± 2.40)μmol/L],高脂组为[(35.7 ± 14.1)μmol/L]。相关性分析表明,空腹血糖、空腹胰岛素、HOMA-IR和内脏脂肪均是影响血浆同型半胱氨酸的因素。逐步回归检验显示,仅空腹血糖(r = 0.504,P = 0.031)和HOMA-IR(r = 0.302,P = 0.046)独立影响血浆同型半胱氨酸水平。
得出结论,吡格列酮可降低高脂饮食诱导的胰岛素抵抗Wistar大鼠的血浆同型半胱氨酸水平。